Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

The acquisition in brief Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize ...

AEON Biopharma, Inc. announced in its press release that it is advancing its biosimilar development program for ABP-450, a botulinum toxin complex, by initiating analytical studies to prepare for ...

China's Bio-Thera Solutions has entered into an exclusive commercialization agreement with India's Dr. Reddy's Laboratories ...

The Board of Directors of the African Development Bank (the "AfDB") has approved a EUR 15 million senior corporate loan to Minapharm Pharmaceuticals S.A.E. (Minapharm), a leading biopharmaceutical ...